Matinas BioPharma Holdings (MTNB) filed a registration statement on Tuesday for the potential sale of up to $150 million in securities.
The filing covers common and preferred stock, warrants, debt securities, subscription rights and units.
Net proceeds will be used for working capital and general corporate purposes.